2-硝基-3-氯-苯甲酰氯 | 19088-99-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-3-氯-苯甲酰氯
• 英文名称: 3-chloro-2-nitrobenzoyl chloride
• CAS: 19088-99-4
• 化学式: C₇H₃Cl₂NO₃
• 分子量: 220.012
• InChiKey: ZNBNVUUCAFMGIK-UHFFFAOYSA-N

物化性质

• 熔点：
  50-56 °C
• 沸点：
  316.9±22.0 °C(Predicted)
• 密度：
  1.575±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2-硝基-3-氯-苯甲酰氯 在 氢氧化钾 、 ammonium hydroxide 、 溴 作用下， 反应 25.58h， 生成 3-(1-Imidazolyl)-2-nitroaniline
  参考文献：
  名称：

  Cardiotonic agents. Synthesis and cardiovascular properties of novel 2-arylbenzimidazoles and azabenzimidazoles

  摘要：

  Novel 2-arylbenzimidazoles and azabenzimidazoles were synthesized, and their inotropic action was evaluated. Changes in left ventricular pressure, dP/dt max, were measured as an index of cardiac contractility. The structural features that impart optimal inotropic activity are presented. The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers. To investigate the mechanism of action, the most potent compounds were tested for their calcium-sensitizing properties and their potential for the inhibition of phosphodiesterase. Two compounds, 1 and 4 1, showed interesting in vitro and oral activity without side effects. They have a more potent calcium-sensitizing effect than MCI-154 and are under futher investigation.

  DOI：

  10.1021/jm00101a024
• 作为产物：
  描述：

  3-氯-2-硝基苯甲酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-硝基-3-氯-苯甲酰氯
  参考文献：
  名称：

  作为ERK-MAP激酶信号传导途径的特异性抑制剂的硫代黄酮衍生物的合成与构效关系。

  摘要：

  硝基苯甲醛3和α-[对-（对甲氧基苄硫基）苯甲酰基]亚砜4的缩合得到α-亚磺酰基烯酮5。用甲酸处理5引起环化，然后脱苄基化得到3-（甲基亚磺酰基）硫代黄酮6。双键通过在苯中回流6进行消除亚甲磺酸的生成，最后，在四氟硼酸中用锡还原2-苯基-4H-1-苯并噻喃-4-酮（硫代黄酮）7的硝基。评价由此制备的各种2'-氨基硫代黄酮8对ERK-MAP激酶途径的抑制作用。在基于细胞的实验中，2-（2'-氨基-3'-甲氧基苯基）-4H-1-苯并噻喃-4-酮（8b）的抑制作用比相应的含氧化合物（PD98059，1）关于Raf诱导的ERK-MAP激酶途径的激活以及细胞增殖。此外，化合物8b选择性和有效地抑制其中ERK-MAP激酶途径被组成性激活的肿瘤细胞的增殖。

  DOI：

  10.1016/j.bmc.2004.02.002
• 作为试剂：
  描述：

  N,N'-二环己基碳二亚胺 、 ethyl 1,2,3,4-tetrahydro-β-carboline-3-carboxylate 在 2-硝基-3-氯-苯甲酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以51%的产率得到2-(3-Chloro-2-nitro-benzoyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis of β-carboline-benzodiazepine hybrid molecules and their “amputated” analogues as novel ligands of the benzodiazepine receptor

  摘要：

  DOI：

  10.1016/s0040-4020(01)85462-4

文献信息

• Structure–Activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors
  作者：Yuo-Ling Chou、David D Davey、Keith A Eagen、Brian D Griedel、Rushad Karanjawala、Gary B Phillips、Karna L Sacchi、Kenneth J Shaw、Shung C Wu、Dao Lentz、Amy M Liang、Lan Trinh、Michael M Morrissey、Monica J Kochanny

  DOI：10.1016/s0960-894x(02)00938-1

  日期：2003.2

  non-amidine factor Xa inhibitor with good selectivity against thrombin and trypsin. A series of modifications of the three aromatic groups of 1 was investigated. Substitution of chlorine or bromine for fluorine on the aniline ring led to the discovery of subnanomolar factor Xa inhibitors. Positions on the anthranilic acid ring that can accommodate further substitution were also identified.

  通过高通量筛选将化合物1鉴定为对凝血酶和胰蛋白酶具有良好选择性的新型有效非non因子Xa抑制剂。研究了1的三个芳族基团的一系列修饰。用氯或溴取代苯胺环上的氟导致发现亚纳摩尔因子Xa抑制剂。还确定了可以适应进一步取代的邻氨基苯甲酸环上的位置。
• Synthesis and Structure-Activity Relationship Studies of <i>N</i>-monosubstituted Aroylthioureas as Urease Inhibitors
  作者：Wei-Wei Ni、Hai-Lian Fang、Ya-Xi Ye、Wei-Yi Li、Li Liu、Zi-Juan Fu、Dawalamu、Wen-Yan Zhu、Ke Li、Fang Li、Xia Zou、Hui Ouyang、Zhu-Ping Xiao、Hai-Liang Zhu

  DOI：10.2174/1573406416999200818152440

  日期：2021.11

  Thiourea is a classical urease inhibitor which is usually used as a positive control, and many N,N'-disubstituted thioureas have been determined as urease inhibitors. However, due to steric hindrance, N,N'-disubstituted thiourea motif could not bind urease as thiourea. On the contrary, N-monosubstituted thiourea with a tiny thiourea motif could theoretically bind into the active pocket as thiourea.

  A series of N-monosubstituted aroylthioureas were designed and synthesized for evaluation as urease inhibitors.

  Urease inhibition was determined by the indophenol method and IC₅₀ values were calculated using computerized linear regression analysis of quantal log dose-probit functions. The kinetic parameters were estimated via surface plasmon resonance (SPR) and by nonlinear regression analysis based on the mixed type inhibition model derived from Michaelis-Menten kinetics.

  Compounds b2, b11, and b19 reversibly inhibited urease with a mixed mechanism, and showed excellent potency against both cell-free urease and urease in the intact cell, with IC₅₀ values being 90- to 450-fold and 5- to 50-fold lower than the positive control acetohydroxamic acid, respectively. The most potent compound b11 showed an IC₅₀ value of 0.060 ± 0.004μM against cell-free urease, which bound to urea binding site with a very low KD value (0.420±0.003nM) and a very long residence time (6.7 min). Compound b11 was also demonstrated to have very low cytotoxicity to mammalian cells.

  The results revealed that N-monosubstituted aroylthioureas bound to the active site of urease as expected, and represent a new class of urease inhibitors for the development of potential therapeutics against infections caused by urease-containing pathogens.

  背景： 硫脲是一种经典的尿素酶抑制剂，通常用作阳性对照，许多N,N'-二取代硫脲已被确定为尿素酶抑制剂。然而，由于空间位阻，N,N'-二取代硫脲基团无法像硫脲那样结合尿素酶。相反，具有微小硫脲基团的N-单取代硫脲理论上可以像硫脲一样结合到活性口袋中。 目标： 设计并合成了一系列N-单取代芳酰硫脲，用于评估其作为尿素酶抑制剂的效果。 方法： 通过吲哚酚法确定尿素酶抑制作用，并利用量化对数剂量-概率函数的计算机化线性回归分析计算IC50值。通过表面等离子共振（SPR）和基于从迈克尔斯-门特金动力学导出的混合型抑制模型的非线性回归分析估计动力学参数。 结果： 化合物b2、b11和b19以混合机制可逆地抑制尿素酶，并对无细胞尿素酶和完整细胞中的尿素酶表现出极佳的效力，其IC50值分别比阳性对照乙酰羟羟肟酸低90至450倍和5至50倍。最有效的化合物b11对无细胞尿素酶显示出IC50值为0.060 ± 0.004μM，其与尿素结合位点的结合具有非常低的KD值（0.420±0.003nM）和非常长的停留时间（6.7分钟）。化合物b11还被证明对哺乳动物细胞具有非常低的细胞毒性。 结论： 结果表明，N-单取代芳酰硫脲如预期地结合到尿素酶的活性位点，并代表了一类新的尿素酶抑制剂，可用于开发针对含尿素酶病原体引起的感染的潜在治疗药物。
• One-Pot Synthesis of Seven-Membered Heterocyclic Derivatives of Diazepines Involving Copper-Catalyzed Rearrangement Cascade Allyl-Amination
  作者：Yuepeng Chen、Xinglei Liu、Wei Shi、Shilong Zheng、Guangdi Wang、Ling He

  DOI：10.1021/acs.joc.9b02710

  日期：2020.4.17

  trifluoromethanesulfonate as catalysts in the presence of triphenylphosphine. This synthesis process involves nitrene formation, C–H bond insertion, C═C bond rearrangement, and C–N bond formation cascade reactions via copper- and molybdenum-catalyzed mediation. The method features a wide substrate scope and a moderate to high yield (up to 90%), exhibiting the possibility for practical applications

  提出了一种在三苯基膦存在下，以乙酰丙酮钼和三氟甲磺酸铜 (II) 为催化剂，从邻硝基苯甲酸N-烯丙基酰胺合成 1,4-苯二氮卓-5-酮的新型有效方法。该合成过程包括氮烯形成、C-H 键插入、C=C 键重排以及通过铜和钼催化介导的 C-N 键形成级联反应。该方法具有广泛的底物范围和中高产率（高达 90%），具有实际应用的可能性。
• Benzamide derivatives and their use as cytokine inhibitors
  申请人：Astra Zeneca AB

  公开号：US06455520B1

  公开（公告）日：2002-09-24

  The invention concerns amide derivatives of formula (I) wherein R3 is (1-6C)alkyl or halogeno; m is 0-3, p is 0-2 and q is 0-4; each of R1 and R2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R4 is a basic group such as amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, di-[(1-6C)alkyl]amino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; and Q2 is a group such as heteroaryl, heteroaryloxy or heteroaryl-(1-6C)alkoxy which is optionally substituted; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  该发明涉及式(I)的酰胺衍生物 其中R3是(1-6C)烷基或卤素；m为0-3，p为0-2，q为0-4；R1和R2中的每一个是羟基、卤素、三氟甲基和氰基等基团；R4是氨基、(1-6C)烷基氨基、二-[（1-6C）烷基]氨基、二-[（1-6C）烷基]氨基-(1-6C)烷基、二-[（1-6C）烷基]氨基-(2-6C)氧烷基、杂环芳基、杂环芳氧基、杂环芳基-(1-6C)氧烷基、杂环烷基、杂环氧基和杂环烷基-(1-6C)氧烷基；Q2是杂环芳基、杂环芳氧基或杂环芳基-(1-6C)氧烷基等基团，可选择性地被取代；或其药学上可接受的盐或体内可水解酯；它们的制备方法、含有它们的药物组合物以及它们在治疗由细胞因子介导的疾病或医疗状况中的用途。
• Bezamide derivatives for the treatment of diseases mediated by cytokines
  申请人：AstraZeneca AB

  公开号：US06579872B1

  公开（公告）日：2003-06-17

  The invention concerns the use of amide derivatives of formula (I) wherein: R1 and R2 are substituents such as hydroxy, C1-6alkoxy, mercapto, C1-6alkylthio, amino, C1-6alkylamino and di-(C1-6alkyl)amino; m and p are independently 0-3; R3 is C1-4alkyl; q is 0-4; and R4 is aryl or cycloalkyl; or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及使用式（I）的酰胺衍生物，其中：R1和R2是取代基，例如羟基，C1-6烷氧基，巯基，C1-6烷基硫基，氨基，C1-6烷基氨基和二（C1-6烷基）氨基；m和p独立地为0-3；R3为C1-4烷基；q为0-4；而R4为芳基或环烷基；或其药学上可接受的盐制剂，用于制造治疗因细胞因子介导的疾病或医疗条件的药物。